Scribe Therapeutics (NASDAQ:SCTX) Shares Up 7.6% – Here’s What Happened

Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) shares were up 7.6% on Thursday . The stock traded as high as $33.86 and last traded at $33.41. Approximately 25,826 shares traded hands during trading, a decline of 87% from the average session volume of 200,512 shares. The stock had previously closed at $31.05.

Wall Street Analysts Forecast Growth

SCTX has been the topic of several analyst reports. Wall Street Zen raised Scribe Therapeutics to a “hold” rating in a research report on Saturday, August 1st. Guggenheim assumed coverage on Scribe Therapeutics in a report on Tuesday. They issued a “buy” rating and a $50.00 target price for the company. Leerink Partners began coverage on Scribe Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $37.00 price target for the company. Finally, Wells Fargo & Company assumed coverage on Scribe Therapeutics in a report on Tuesday. They set an “overweight” rating and a $60.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $49.00.

Get Scribe Therapeutics alerts:

Get Our Latest Stock Report on Scribe Therapeutics

Scribe Therapeutics Stock Up 21.9%

Insider Buying and Selling at Scribe Therapeutics

In other Scribe Therapeutics news, Director Behzad Aghazadeh purchased 2,383,333 shares of the firm’s stock in a transaction on Friday, July 24th. The shares were acquired at an average cost of $15.15 per share, for a total transaction of $36,107,494.95. Following the completion of the transaction, the director owned 3,080,983 shares of the company’s stock, valued at approximately $46,676,892.45. The trade was a 341.62% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Bio Fund Ii L.P. Ah purchased 333,333 shares of the company’s stock in a transaction dated Monday, July 27th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $4,999,995.00. Following the purchase, the insider directly owned 2,385,075 shares in the company, valued at approximately $35,776,125. The trade was a 16.25% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 3,727,237 shares of company stock worth $56,291,746 over the last quarter.

About Scribe Therapeutics

(Get Free Report)

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.

Further Reading

• Five stocks we like better than Scribe Therapeutics
• AIxCrypto Dumps Its Crypto and Goes All In on Robotics
• AST SpaceMobile’s FCC Test Arrives as Investors Weigh a Costly Q2 Miss
• Viking Stock Fell After Earnings, But the Numbers Tell a Different Story
• 3 Ways to Invest in Cybersecurity Through ETFs

Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.